{"analyses":[{"ciLowerLimit":"0.23","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.60","estimateComment":"The HR was adjusted for World Health Organization (WHO) performance status scale (0 versus 1 at Baseline) and number of prior lines of systemic treatment for advanced disease (0/1 versus 2+).","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"Stratified two-sided log rank p-value for leiomyosarcoma","paramType":"Hazard Ratio (HR)","paramValue":"0.37","statisticalMethod":"Log Rank","testedNonInferiority":false},{"ciLowerLimit":"0.19","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.98","estimateComment":"The HR was adjusted for World Health Organization (WHO) performance status scale (0 versus 1 at Baseline) and number of prior lines of systemic treatment for advanced disease (0/1 versus 2+).","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.005","pValueComment":"Stratified two-sided log rank p-value for synovial sarcoma","paramType":"Hazard Ratio (HR)","paramValue":"0.43","statisticalMethod":"Log Rank","testedNonInferiority":false},{"ciLowerLimit":"0.25","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.60","estimateComment":"The HR was adjusted for World Health Organization (WHO) performance status scale (0 versus 1 at Baseline) and number of prior lines of systemic treatment for advanced disease (0/1 versus 2+).","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"Stratified two-sided log rank p-value for other STS histologies","paramType":"Hazard Ratio (HR)","paramValue":"0.39","statisticalMethod":"Log Rank","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.6","upperLimit":"9.3","value":"8.1"},{"groupId":"OG001","lowerLimit":"13.3","upperLimit":"23.1","value":"20.1"}]}],"title":"Leiomyosarcoma, n=49, 109"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.7","upperLimit":"8.9","value":"4.1"},{"groupId":"OG001","lowerLimit":"8.9","upperLimit":"27.1","value":"17.9"}]}],"title":"Synovial sarcoma, n=13, 25"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.0","upperLimit":"7.9","value":"4.3"},{"groupId":"OG001","lowerLimit":"13.0","upperLimit":"27.1","value":"20.1"}]}],"title":"Other STS, n=61, 112"}],"denoms":[{"counts":[{"groupId":"OG000","value":"123"},{"groupId":"OG001","value":"246"}],"units":"Participants"}],"description":"PFS was defined as the time interval between the date of randomization and the earliest date of either disease progression or death due to any cause. Participants were analyzed for PFS in histology subgroups of STS (as per the World Health Organization \\[WHO\\] classification, 2008): leiomyosarcoma (malignant cancer of smooth muscle), synovial sarcoma (cancer near the joints of the arm or leg), and other STS (without the tumor type of leiomyosarcoma or synovial sarcoma), based on independent review.The Kaplan-Meier method was used for PFS estimates.","dispersionType":"95% Confidence Interval","groups":[{"description":"Matching placebo tablets administered orally once daily for a duration until participants experienced disease progression, death, unacceptable toxicity, or participants withdrew consent","id":"OG000","title":"Placebo"},{"description":"Pazopanib 200 milligrams (mg) and 400 mg film-coated tablets (containing pazopanib monohydrochloride) administered orally at a dose of 800 mg once daily for a duration until participants experienced disease progression, death, unacceptable toxicity, or participants withdrew consent","id":"OG001","title":"Pazopanib"}],"paramType":"MEDIAN","populationDescription":"ITT Population. The \"n\"s in the category titles represent the number of participants in each treatment arm with the indicated STS.","reportingStatus":"POSTED","timeFrame":"From the date of randomization until the date of the first documented progression or the date of death from any cause, whichever came first (assessed for an average of 10 months)","title":"PFS in the Indicated Histology Subgroups of Soft Tissue Sarcoma (STS)","type":"SECONDARY","unitOfMeasure":"weeks"}